Laboratoires Filorga

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Laboratoires Filorga - overview

Established

1978

Location

Paris, -, France

Primary Industry

Consumer Products

About

Founded in 1978, based in France, LABORATOIRES FILORGA provides medical products for dermatologists, aesthetic doctors and plastic surgeons. It also provides skin care products, serums, intensive treatments, programs, and interventionals.


Primary Industry

Consumer Products

Sub Industries

Beauty & Hygiene, Paper/Soft Products, Biomaterials

Website

www.filorga.com

Verticals

Manufacturing

Total Amount Raised

Subscriber access only

Laboratoires Filorga - financials

Fiscal Year EndedDec 31, 2019Dec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024
Revenue (USD)215,335,252163,808,053134,177,480---
% Revenue Growth (YoY)-(23.9%)(18.1%)---
EBITDA (USD)58,562,63023,659,375(2,099,071)---
Operating Income (USD)58,199,60317,287,080(3,333,478)---
Operating Margin27.0%10.6%(2.5%)---
% EBITDA Margin27.2%14.4%(1.6%)---
NET Income (USD)40,864,68312,374,266(1,866,603)---
% Net Margin19.0%7.6%(1.4%)---

Laboratoires Filorga - deals

Deals TypeDeal StatusTarget (s)Deal DateInvestor(s)Seller(s)Deal size (Mn)Enterprise value (Mn)Post-money valuation (Mn)EBITDA multiple (x)Revenue multiple (x)Lead partner (s)
Unspecified ExitCompletedLaboratoires Filorga-
BuyoutCompletedLaboratoires Filorga-

Displaying 1 - 2 of 2

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.